This article is more than 5 years old. Information may no longer be current.
Tranexamic acid cost-effective for decreasing blood loss, transfusions after THA, TKA
Click Here to Manage Email Alerts
For patients who underwent elective total hip arthroplasty or total knee arthroplasty, the standardized administration of tranexamic acid was an effective and cost-effective strategy for decreasing blood loss and transfusions, according to recently published data.
Researchers conducted a process improvement project standardizing tranexamic acid (TXA) administration to patients who underwent total hip arthroplasty (THA) and total knee arthroplasty (TKA). They compared patients 12 months before implementation of the project and after the project was implemented.
TXA administration increased after implementation of the project, per study results. Investigators reported the increase in TXA administration correlated with a decreased in perioperative hemoglobin decrement, patients transfused and the number of units transfused per patients.
Further, the cost savings per patient was $128, or $55,884 for the annual program wide. The THA subgroup saw the most savings. Adverse effects did not increase. – by Monica Jaramillo
Disclosure : Demos reports he is a board or committee member of the American Association of Orthopaedic Surgeons. Please see the full study for a list of all other authors’ relevant financial disclosures.
Click Here to Manage Email Alerts